Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Receives Average Rating of “Moderate Buy” from Analysts

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $55.80.

PTHS has been the topic of a number of recent research reports. Piper Sandler initiated coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of Pelthos Therapeutics in a research note on Wednesday, April 1st. They set an “overweight” rating and a $50.00 target price on the stock. Oppenheimer lifted their target price on shares of Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a research note on Friday, May 15th. Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 24th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Pelthos Therapeutics in a research note on Thursday, March 19th.

Pelthos Therapeutics Stock Performance

PTHS opened at $27.50 on Monday. The firm has a market capitalization of $95.70 million, a price-to-earnings ratio of -1.33 and a beta of 3.17. Pelthos Therapeutics has a twelve month low of $11.20 and a twelve month high of $54.29. The stock’s 50-day simple moving average is $25.10. The company has a quick ratio of 1.86, a current ratio of 2.79 and a debt-to-equity ratio of 1.41.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share for the quarter. The company had revenue of $10.91 million for the quarter. As a group, analysts predict that Pelthos Therapeutics will post -11.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pelthos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Pale Fire Capital SE raised its stake in shares of Pelthos Therapeutics by 59.5% in the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after acquiring an additional 4,819 shares during the period. Knott David M Jr raised its stake in shares of Pelthos Therapeutics by 9.3% in the 1st quarter. Knott David M Jr now owns 21,073 shares of the company’s stock valued at $443,000 after acquiring an additional 1,792 shares during the period. Ikarian Capital LLC raised its stake in shares of Pelthos Therapeutics by 309.5% in the 4th quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after acquiring an additional 193,307 shares during the period. Millennium Management LLC purchased a new stake in shares of Pelthos Therapeutics in the 4th quarter valued at approximately $343,000. Finally, Boothbay Fund Management LLC raised its stake in shares of Pelthos Therapeutics by 279.8% in the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock valued at $2,501,000 after acquiring an additional 59,435 shares during the period. 77.96% of the stock is owned by hedge funds and other institutional investors.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).